We are live on ! Find out more
PLRX icon

Pliant Therapeutics

0.6674 USD
+0.0072
1.09%
At close Updated Nov 18, 10:06 AM EST
1 day
1.09%
5 days
-13.88%
1 month
-25.74%
3 months
-41.97%
6 months
-43.44%
Year to date
-46.61%
1 year
-57.49%
5 years
-95.75%
10 years
-96.87%
 

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Employees: 49

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
5 days ago
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment  Pliant's proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
9 days ago
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Neutral
GlobeNewsWire
19 days ago
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
Neutral
GlobeNewsWire
29 days ago
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company's integrin-mediated delivery platform
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Neutral
GlobeNewsWire
29 days ago
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026.
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Neutral
GlobeNewsWire
1 month ago
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Leader in targeted immuno-oncology drug development  brings three decades of academic and biopharmaceutical oncology expertise
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Neutral
GlobeNewsWire
3 months ago
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Neutral
GlobeNewsWire
3 months ago
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095,  experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
4 months ago
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Appointments bring global oncology drug development experience  and deepen Board's operational and regulatory expertise
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Neutral
Seeking Alpha
5 months ago
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Price charts implemented using Lightweight Charts™